POD12 in mantle cell lymphoma: comparison with POD24, post-progression survival, and BTK inhibitor exposure
Annals of Hematology · 11.11.2026
DOI: 10.1007/s00277-026-07352-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 11.11.2026. Verfasst von Jin Chai und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science Foundation of Peking University Cancer Hospital.
Abstract (Originalsprache)
Background
Early progression after first-line therapy identifies high-risk mantle cell lymphoma (MCL), but its post-progression implications and subsequent treatment patterns remain incompletely defined. Patients and methods We retrospectively analyzed 216 newly diagnosed MCL patients treated at two Chinese centers from 2010 to 2022. Progression of disease within 12 months (POD12) was defined as progression, relapse, or death within 12 months after initiation of first-line therapy. Post-progression survival (PPS) and subsequent-line Bruton tyrosine kinase inhibitor (BTKi) exposure were evaluated. First-line treatment was heterogeneous: R-CHOP-like (49.5%), cytarabine-containing/intensive (26.9%), BTKi-containing (10.6%), bendamustine plus rituximab (2.8%), and other regimens (10.2%).
Results
Among 209 POD12-evaluable patients, 68 (32.5%) experienced POD12. Elevated lactate dehydrogenase (LDH; OR, 2.31; 95% CI, 1.19–4.46; P = 0.01) and Ki-67 ≥ 50% (OR, 2.37; 95% CI, 1.17–4.82; P = 0.02) were independently associated with POD12. In the 12-month landmark cohort, POD12 was associated with inferior subsequent overall survival (HR, 5.20; 95% CI, 3.13–8.63; P 12– ≤ 24, and > 24 months was 22.1 months, 42.1 months, and not reached, respectively (overall log-rank P < 0.001). Subsequent-line BTKi exposure was associated with longer PPS overall (adjusted HR, 0.23; 95% CI, 0.13–0.38) and among POD12 patients (adjusted HR, 0.24; 95% CI, 0.12–0.46).
Conclusion
POD12 identifies a high-risk MCL subset with poor subsequent survival, while subsequent-line BTKi exposure is associated with improved PPS, including in POD12 patients; these associations should not be interpreted as causal.
Förderung
- National Natural Science Foundation of China
- Science Foundation of Peking University Cancer Hospital
Zitieren
APA
Chai, J., Lei, X., Song, Y., & Yu, H. (2026). POD12 in mantle cell lymphoma: comparison with POD24, post-progression survival, and BTK inhibitor exposure. Annals of Hematology. https://doi.org/10.1007/s00277-026-07352-y
Vancouver
Chai J, Lei X, Song Y, Yu H. POD12 in mantle cell lymphoma: comparison with POD24, post-progression survival, and BTK inhibitor exposure. Annals of Hematology. 2026. doi:10.1007/s00277-026-07352-y
BibTeX
@article{Chai2026,
author = {Chai, Jin and Lei, Xuewen and Song, Yuqin and Yu, Hui},
title = {POD12 in mantle cell lymphoma: comparison with POD24, post-progression survival, and BTK inhibitor exposure},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07352-y}
}
EUVIMED